



Figure S1 Flowchart of study population. GGO, ground-glass opacity; CT, computed tomography.

Table S1 Patient background (n=90)

Variable	Number of patients
Demographics	
Age (y)	68 [61–72]
SUVmax on FDG-PET	5.10 [3.38–7.13]
Serum CEA level	3.9 [2.1–7.6]
Sex (male), n (%)	61 (67.8)
Smoking, n (%)	
Non-smoker	32 (35.6)
Ex-smoker	37 (41.1)
Current smoker	21 (23.3)
Surgical procedure, n (%)	
Lobectomy	80 (88.9)
Segmentectomy/sublobar	10 (11.1)
EGFR, n (%)	
Mutant	27 (30.0)
WT	63 (70.0)

Data are shown as median [IQR] or n (%). SUVmax, maximum standard uptake value; FDG PET, [¹⁸F] fluorodeoxyglucose positron emission tomography; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; WT, wild type; IQR, interquartile range.

Table S2 The distribution of 3DSV in patients with recurrence and non-recurrence

Variables*	Recurrence (n=26), n [%]	Non-recurrence (n=64), n [%]
0–520 (mm ³)	1 [4]	12 [19]
520–4,180 (mm ³)	14 [54]	39 [61]
4,180–14,130 (mm ³)	9 [35]	13 [20]
14,130– (mm ³)	2 [7]	0 [0]

*, this category was separated by converted tumor diameter. 520 mm³, 4,180 mm³ and 14,130 mm³ correspond to 10 mm, 20 mm and 30 mm in converted diameter, respectively. 3DSV, three-dimensional solid volume between 0 and 199 HU.